Drug Profile
Research programme: bacteriophage-based therapies - BiomX
Latest Information Update: 13 Aug 2021
Price :
$50
*
At a glance
- Originator BiomX
- Class Anti-inflammatories; Antibacterials; Bacteriophages
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Peritonitis
- No development reported Clostridium difficile infections; Prevotella infections
Most Recent Events
- 13 Aug 2021 Pharmacodynamics data from preclinical studies in Peritonitis presented at the World Microbe Forum 2021 (WMF-2021)
- 28 Sep 2020 No recent reports of development identified for research development in Clostridium-difficile-infections in Israel
- 28 Sep 2020 No recent reports of development identified for research development in Prevotella-infections in Israel